Penn Today interviewed John Swartley, Associate Vice Provost and PCI’s Managing Director about the organization’s role in translating discoveries and ideas at Penn into businesses and products for societal benefit.
In the article, Swartley discusses selected key highlights from FY22, including the major impact Penn technologies have made towards providing life-saving and life-protecting medicines to billions of patients worldwide. Penn expertise and technologies licensed from the University, he further explains, are key components in nearly two dozen FDA-approved drugs and devices (including the two currently approved mRNA-based COVID vaccines), which are directly impacting and improving human lives.
Swartley also expressed his gratitude to his predecessor Mike Cleare, his visionary boss Dawn Bonnell, former President Amy Gutmann, and Penn’s entire executive leadership team and Board of Trustees for their support and encouragement of innovation at Penn. Read the full article here.
